Mei Ri Jing Ji Xin Wen·2025-10-31 06:04Core Viewpoint - The Hong Kong stock market is experiencing a downturn, with the Hang Seng Technology Index declining significantly, while innovative pharmaceutical stocks are performing well amidst a broader market weakness [1][2]. Group 1: Market Performance - On October 31, the three major indices in Hong Kong fell, with the Hang Seng Technology Index seeing an afternoon drop of 2% [1]. - Technology stocks broadly declined, while innovative pharmaceutical stocks rose against the trend [1]. - The semiconductor sector weakened, with major stocks like Hua Hong Semiconductor and SMIC experiencing significant declines of over 7% and 5%, respectively [1]. Group 2: Economic Outlook - According to recent research from China Merchants Securities, the combination of the Federal Reserve's interest rate cuts and an unexpected end to balance sheet reduction is favorable for global risk assets [1]. - Despite hawkish comments from Powell increasing uncertainty around the rate cut path, the trend towards easing is clear, suggesting that current market dips may present buying opportunities [1]. - The institution anticipates a 25 basis point rate cut in December and three additional cuts in the following year, which is more aggressive than market expectations [1]. Group 3: Investment Recommendations - The institution believes that the dual easing policies from the US and China will benefit risk assets, with Hong Kong stocks expected to enter a "slow bull" market due to strong foreign capital inflows [2]. - The Hang Seng Technology Index ETF is currently valued at 23.50 times earnings, which is approximately 32.84% below historical averages, indicating a safety margin for investors [2]. - The report suggests focusing on leading internet technology companies, high-end manufacturing related to AI, AI-related power sectors, and selectively investing in innovative pharmaceutical stocks [2].